PDA

View Full Version : PrimeGen Biotech Presents on the Therapeutic Potential of Reprogrammed Germ-Line Stem Cells at Keystone Symposium on Stem Cells, Senescence and Cancer in Singapore



Leif
10-28-2005, 11:40 AM
http://www.pharmalive.com//News/index.cfm?articleid=285168&categoryid=40




SINGAPORE and IRVINE, Calif., October 27, 2005 /PRNewswire/ -- PrimeGen Biotech, LLC, a 3 year old privately-held stem cell engineering firm, announced today that it will present results of its research on the therapeutic reprogramming of murine germ-line stem cells at the Keystone Symposium on Stem Cells, Senescence and Cancer, currently being held in Singapore. The poster presentation will occur on Friday, October 28 from 3:30 to 5:30 PM at the conference.




The company's data demonstrate that post-natal murine germ-line stem cells, which normally differentiate only into sperm and eggs, can be reprogrammed to be pluripotent. These reprogrammed germ-line stem cells, which the company has termed PrimeCell(TM), express embryonic stem cell (ESC)-specific markers and were successfully directed to differentiate into multiple tissue types, including cardiac muscle and neural cell types. The data also demonstrate that therapeutically reprogrammed germ-line stem cells injected into mouse blastocysts give rise to all three germ layers in the murine embryo, substantiating the finding that the cells are pluripotent.

Unlike existing embryonic stem cell lines or adult stem cell lines from any other known source, germ-line stem cells possess a uniquely conserved genome. These cells have been evolutionarily conserved to maintain the highest level of genetic integrity, which enables successful propagation of species. "Our work with murine spermatogonial stem cells demonstrates the potential to apply our therapeutic reprogramming approach to human-derived germ-line cells for the development of regenerative therapies," said Francisco Silva, Executive Vice President of R&D at PrimeGen. "Because of PrimeCell's unique genetic integrity, conditioned pluripotentiality and the fact that it is derived from a post-natal source, we believe it will be the most therapeutically valuable stem cell available to treat a wide range of degenerative disorders."

More on link above.

Leif
11-17-2005, 02:12 PM
http://www.pharmalive.com//News/index.cfm?articleid=291935&categoryid=15




KYOTO, Japan and IRVINE, Calif., November 16, 2005 /PRNewswire/ -- PrimeGen Biotech announced today the presentation of preliminary data on their human pluripotent stem cell platform at the 1st International Symposium on Germ Cells, Epigenetics, Reprogramming and Embryonic Stem Cells, currently being held in Kyoto, Japan. The presentation describes PrimeGen's method of deriving pluripotent stem cells from an adult source, previously thought possible only from embryonic stem cells.



PrimeGen Biotech applied its proprietary therapeutic reprogramming process to human adult germ-line stem cells, termed PrimeCell(TM). The company expects the human cells will also prove to be pluripotent, replicating results derived from murine models where germ-line stem cells were shown to be pluripotent after therapeutic reprogramming. Germ-line stem cells naturally form only the reproductive gamete cells: sperm and eggs.
Reprogrammed germ-line stem cells are a promising new stem cell type and may have unique advantages over other stem cell lines. Germ-line stem cells have been shown to contain an evolutionarily conserved genome, which is essential for species propagation. "If these stem cells incurred the same damages or underwent the aging mechanism as other cells, the genomes of egg and sperm cells would become compromised and eventually a species would not be able to successfully produce new offspring. Our approach is designed to allow us to harness the germ-line stem cell's essentially uncompromised genetic material and direct it to differentiate into other cell types, like cardiomyocytes, which will inherit the parent cells' high quality cellular constituents," said K.-Y. Francis Pau, Ph.D., Director of Research and Development at PrimeGen Biotech. "We are hopeful that these essentially new cellular constituents will enable PrimeCell(TM) differentiated cell lines to perform superior functional repair for added therapeutic benefit."

More on link above.